Brain natriuretic peptide (BNP) was originally identified in extracts of porcine brain. However, in humans, it is produced mainly in the cardiac ventricles in response to excessive stretching of heart muscle cells (cardiomyocytes); high concentrations of BNP in the blood are a marker of heart failure. BNP is also known as natriuretic peptide B, gamma-brain natriuretic peptide, and GC-B. The release of BNP is controlled by calcium ions. BNP binds to and activates the atrial natriuretic factor receptors NPRA and NPRB, similar to atrial natriuretic peptide (ANP) but with much lower affinity. Both BNP and ANP cause a net decrease in blood volume, which lowers the body's blood pressure. Recombinant BNP is used to treat decompensated heart failure.
This product is an affinity-purified IgG antibody that recognizes human BNP. The antibody was raised in rabbit using a synthetic peptide, and can be used for immunohistochemical (IHC) detection of human BNP.